
Overview
Zakłady Farmaceutyczne Polpharma is the largest Polish manufacturer of pharmaceuticals and active pharmaceutical ingredients. The company actively operates in the markets of Central and Eastern Europe, the Caucasus, and Central Asia.
- ul. Metalowca 2, 39-460 Nowa Dęba
- ul. Władysława Łokietka 10, 98-200 Sieradz
- ul. Bobrowiecka 6, 00-728 Warszawa
- ul. Ożarowska 28/30, 05-850 Ożarów Mazowiecki
Financials
Revenue history (in m)
Filing timeliness
Financial statements were filed on time, on average 44 days early. All were audited by a statutory auditor.
- 202514/05/2026
- 202414/05/2025
- 202308/07/2024
- 202229/06/2023
- 202107/07/2022
- 202028/06/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News
The future of science chooses Polpharma. Company leads the Universum 2026 ranking
Polpharma strengthens its position in Central and Eastern Europe. Biofarm – leader of the Romanian market – joins the Group
Polish RNA Technology Platform
Well-being of female and male doctors under scrutiny – results of the first nationwide study among medical professionals
Polpharma Scientific Foundation announces the start of the 25th edition of the Foundation Grant competition.
Industry
Offer
- Medicines
- Pharmaceutical substances
- Pharmaceutical products
Websites
The company has 12 websites. The sites are available in: Polish and English. The company measures traffic with Google Analytics and uses the Meta advertising pixel (Facebook, Instagram).
- polpharma.plStrona główna – PolpharmaWordPressGoogle AnalyticsGoogle Tag ManagerYoast SEOApache
- acidolac.plAcidolac | Suplement diety | Przyjaciel dziecięcych brzuszkówWordPressYoast SEOApache
- allertec.plAllertec® Effect – na objawy alergiiWebflowGoogle Tag ManagerCloudflare
Public procurement
25 tenders recorded as contracting authority.
Notices (contracting authority)
| Publication date | Subject | Amount | Type | |
|---|---|---|---|---|
| Jan 11, 2017 | Poland-Starogard Gdański: Biomedical equipment | –– | Contract award notice | |
| Jan 11, 2017 | Poland-Starogard Gdański: Laboratory, optical and precision equipment (except glass) | –– | Contract award notice | |
| Jan 11, 2017 | Poland-Starogard Gdański: Laboratory, optical and precision equipment (except glass) | –– | Contract award notice |
The company is the contractor in one public sector contract, worth USD 8.69k.
| Signed on | Subject | Amount | Public buyer | |
|---|---|---|---|---|
| Sep 8, 2026 | Medication donation | $8,690 | Wojewódzki Szpital Zdrowia Psychicznego Im. Dr. Józefa Bednarza w Świeciu |
Trademarks
The company currently holds no active trademarks with the Polish Patent Office. 293 marks have expired or were not registered. The first mark was filed in 1987.
| Mark | Number | Classes | Status | Protected until | |
|---|---|---|---|---|---|
| Sonidex | Z.401799 | 5 | Expired | – | |
| LAZUREX | Z.401798 | 5 | Expired | – | |
| Moxiten | Z.392183 | 5 | Expired | – | |
| Optilamid | Z.391987 | 5 | Expired | – | |
| Glitecur | Z.391986 | 5 | Expired | – |
| Mark | Protected until | |
|---|---|---|
| Sonidex | – | |
| LAZUREX | – | |
| Moxiten | – | |
| Optilamid | – | |
| Glitecur | – |
Job offers
The company has its own careers page: polpharma.pl/praca-w-polpharmie.
Authorized Representatives
Manner of representation
Joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations of will and sign on behalf of the company.
Supervisory board
Ownership
| Owner |
|---|
Polpharma Group Holding B.v. |
Beneficial owners
| Person | Rights |
|---|---|
Capital group
The company is the parent company of a corporate group.
| Name | Ownership |
|---|---|
| 100% | |
Polpharma Biuro Hanlowe Sp. z o.o. | 100% |
| 100% |
Bank accounts
Registered as a VAT taxpayer on 1993-07-05.
69 1030 1117 0000 0000 0101 7222
38 1050 0086 1000 0090 8221 2631
88 1600 1374 1846 6562 1000 0012
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
12 notices recorded in the Court and Commercial Gazette (MSiG).
| Publication date | Event | |
|---|---|---|
| Sep 30, 2026 | Bankruptcy notice | |
| Feb 1, 2024 | Merger registered | |
| Jan 12, 2024 | Merger registered | |
| Apr 27, 2021 | Merger registered | |
| Jan 18, 2021 | Shareholders' meeting convened |
Public aid
48 public aid cases recorded, with a total value of $202,480,103.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 31, 2026 | Regional investment aid | –– | PIERWSZY MAZOWIECKI URZĄD SKARBOWY W WARSZAWIE | |
| Mar 31, 2026 | Regional investment aid | –– | PIERWSZY MAZOWIECKI URZĄD SKARBOWY W WARSZAWIE | |
| Dec 19, 2025 | Aid for research and development projects: experimental development | –– | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
7 projects co-financed from European Funds recorded, with total EU co-financing of $22,474,941.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-09-01 | Development of an innovative technological and analytical platform for the production of medicines containing oligonucleotides in ready-to-use form. | $7.7M$7,651,569 | European Funds for a Modern Economy | |
| 2024-11-01 | Development and advancement of an innovative solution – a complex, two-component medicinal product targeting the treatment of hypertension | $2.5M$2,467,546 | European Funds for a Modern Economy | |
| 2023-11-01 | Development of a tool using artificial intelligence algorithms to forecast sales volumes and plan marketing strategies for pharmaceutical products | $2.6M$2,632,074 | European Funds for a Modern Economy |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| Integrated permit | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Adamed Pharma S.A. | $541,927,181.76 | adamed.com.pl | ||
| Teva Operations Poland sp. z o.o. | $529,423,373.78 | teva.pl | ||
| Fresenius Kabi Polska sp. z o.o. | $247,097,438.47 | fresenius-kabi.com | ||
| Delpharm Poznań S.A. | $110,900,246.81 | delpharm.com | ||
| Tarchomińskie Zakłady Farmaceutyczne Polfa S.A. | $102,988,448.02 | polfa-tarchomin.com.pl | ||
| Natur Produkt Pharma sp. z o.o. | $93,854,070.54 | nppharma.pl | ||
| ICN Polfa Rzeszów S.A. | $85,044,250.03 | icnpolfa.pl | ||
| Celon Pharma S.A. | $51,765,221.75 | celonpharma.com | ||
| Wörwag Pharma Operations sp. z o.o. | $46,828,794.87 | woerwagpharma.pl | ||
| Phytopharm Klęka S.A. | $46,154,888.31 | phytopharm.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-09-30 | Share capital increase (100,207,830.00 PLN → 101,015,400.00 PLN) | |
| 2009-07-10 | Share capital reduction (105,292,020.00 PLN → 100,207,830.00 PLN) | |
| 2007-11-15 | Share capital reduction (226,429,050.00 PLN → 105,292,020.00 PLN) | |
| 2004-01-27 | Share capital increase (202,619,050.00 PLN → 226,429,050.00 PLN) | |
| 2002-08-22 | Entered in the register |
FAQ
Last updated: 2026-10-07